The study compared the i-FACTOR biologic bone graft to autologous bone delivered via interbody fusion cages in single and multilevel PLIF. A radiologic fusion rating for patients treated with i-FACTOR showed a 97.8 percent fusion rate, compared with an 82.2 fusion rate for patients treated with the autograft after one year.
The company received the CE Mark in 2008 for the i-FACTOR and is currently being evaluated by the FDA for clearance in the United States.
Read the Cerapedics release about i-FACTOR.
– Titan Spine Receives FDA 510(k) Clearance on PLIF Device
– Study: No Difference Between Iliac Bone Graft and Local bone Graft for PLIF
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
